Guangsheng Tang: The first-class innovative hepatitis B treatment drug, Narekewei GST-HG141, has completed patient enrollment for Phase III clinical trials.

2026-02-04 08:43:51

Guangsheng Tang announces that the Phase III clinical trial of the innovative hepatitis B treatment drug, Nairikewei GST-HG141, has recently completed enrollment of all subjects, totaling 578 cases. GST-HG141 is used in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial for patients with chronic hepatitis B (CHB) who have a poor response to antiviral therapy. The main goal is to evaluate the efficacy and safety of GST-HG141 in CHB patients who have not responded well to antiviral treatment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.